Key result
Formulary Monograph Service provides monthly monographs and evaluations for newly released and late-phase drugs.
Key points are not available for this paper at this time.
Design
Monograph summary and drug utilization evaluation service
Answers are grounded in this paper and cite their sources.
Enables timely formulary decisions on emerging agents; extends P&T resources with late-phase trial summaries.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2011 monograph topics are on rivaroxaban, ezogabine, fentanyl nasal spray, belatacept, and nitroglycerin ointment 0.4%. The DUE/MUE is on rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2011) studied this question. The Formulary Monograph Service provides monthly monographs and drug utilization evaluations on newly released drugs or those in late phase 3 trials.
Synapse has enriched 10 related papers. Consider them for comparative context: